Culture Collections

A new cohort of iPSC lines available from EBiSC will accelerate research into Huntington’s disease

EBiSC2

The European Bank for induced Pluripotent Stem Cells (EBiSC) and CHDI Foundation have collaborated with Censo Biotechnologies to generate a cohort of 45 iPSC lines derived from Huntington’s disease (HD) gene-expansion carriers (HDGECs) and associated controls. These new lines will be used to further investigate the mechanisms of HD progression and for the development of novel therapeutics. They will be widely available to any interested researcher.

“These iPSC lines offer great promise as a model system for HD research and therapeutic development, a terrible disease that devastates families across multiple generations,” explains Dan Felsenfeld, Director of Stem Cell Biology & Regenerative Medicine at CHDI.  “A major focus of CHDI’s mission is to make resources such as these widely available to researchers to stimulate new research, as well as to support ongoing work of established investigators.”

The donor samples were collected by researchers at University College London and Ulm University Medical Center in collaboration with CHDI. Donors included male and female volunteers aged 30 to 59 years; samples from HDGECs carry CAG expansions ranging from 41 through 50 repeats. Specific CAG-repeat data associated with individual iPSC lines is available via the EBiSC catalogue. Researchers interested in obtaining these lines should visit cells.ebisc.org/ and search ‘CHDI’. All EBiSC iPSC lines are distributed through ECACC’s global distribution network.

Logos

The EBiSC2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement No 821362. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

 

Back to top
Copyright © Public Health England.

Please confirm your country of origin from the list below.